Since Dr. David Kaslow oversaw the creation of Vaxfectin while CSO at Vical, WHY is PATH not using it?
Dr. David Kaslow is director of the PATH Malaria Vaccine Initiative (MVI).
PATH is an international nonprofit organization that transforms global health through innovation. We take an entrepreneurial approach to developing and delivering high-impact, low-cost solutions, from lifesaving vaccines and devices to collaborative programs with communities. Through our work in more than 70 countries, PATH and our partners empower people to achieve their full potential.
At MVI, we know that milestones are reached through collaborations and partnerships. The RTS,S project brings together one of the world’s largest pharmaceutical companies, GlaxoSmithKline, African research centers in seven countries, and partners from US government agencies as well as research institutions across Europe.
Every major Vaccine company is working with PATH... It would seem that David has been in a strong position at Merck, and now PATH to drive usage of Vaxfectin, if it is the breakthrough adjuvant that Vijay suggests.....
Maybe Vaxfectin is just one of a string of overly hyped programs that Vijay pumps like a carnival barker?